Ebola Outbreak in Congo Prompts Urgent Vaccine Development
Summary
A rare Ebola virus species in Congo has prompted urgent vaccine development efforts by Oxford University, Moderna, and IAVI amid fears of a historic epidemic.
Key Points
- A rare Ebola virus species 'Bundibugyo' is causing an epidemic in Congo and surrounding areas.
- More than 1,000 suspected Ebola patients are reported in DR Congo and confirmed infections in Uganda.
- Three major groups—Oxford University, Moderna, and IAVI—are developing vaccines targeting Bundibugyo Ebola.
- Existing Zaire Ebola vaccine is being modified by IAVI, while Moderna and Oxford use their distinct technologies for new vaccines.
